YCM
PLSE icon

Yakira Capital Management’s Pulse Biosciences PLSE Stock Holding History

Yakira Capital Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,313
Closed -$127K – 272
2024
Q2 		$127K Buy
+11,313
New +$107K 0.05% 118

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Yakira Capital Management's PLSE Position: Q3 2024 in Review

Yakira Capital Management sold out of Pulse Biosciences (PLSE) in Q3 2024, closing a stake of 11,313 shares — an estimated $127K sold.

Yakira Capital Management first reported a position in PLSE in Q2 2024 and held it in 1 quarter. The position peaked at $127K in Q2 2024. 72 funds tracked by Wall St. Rank hold PLSE as of Q3 2024.

  • Yakira Capital Management reported no remaining Pulse Biosciences position as of Q3 2024 after selling out during the quarter.
  • Yakira Capital Management sold 11,313 Pulse Biosciences shares in Q3 2024, an estimated $127K.
  • Yakira Capital Management first reported a position in Pulse Biosciences in Q2 2024 and held it in 1 quarter.
  • Yakira Capital Management's Pulse Biosciences position peaked at $127K in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2024.

Based on Yakira Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.